193 related articles for article (PubMed ID: 10593354)
21. [Inhibition of the COMPT with entacapone in the treatment of motor fluctuations in Parkinson disease].
Kulisevsky J
Neurologia; 1999; 14(7):349-58. PubMed ID: 10570622
[TBL] [Abstract][Full Text] [Related]
22. Replacing a dopamine agonist by the COMT-inhibitor tolcapone as an adjunct to L-dopa in the treatment of Parkinson's disease: a randomized, multicenter, open-label, parallel-group study.
Ries V; Selzer R; Eichhorn T; Oertel WH; Eggert K;
Clin Neuropharmacol; 2010 May; 33(3):142-50. PubMed ID: 20502133
[TBL] [Abstract][Full Text] [Related]
23. Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson's disease.
Lyytinen J; Kaakkola S; Ahtila S; Tuomainen P; Teräväinen H
Mov Disord; 1997 Jul; 12(4):497-505. PubMed ID: 9251066
[TBL] [Abstract][Full Text] [Related]
24. New options for treatment of Parkinson's disease.
LeWitt PA
Baillieres Clin Neurol; 1997 Apr; 6(1):109-23. PubMed ID: 9426871
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of catechol-O-methyltransferase contributes to more stable levodopa plasma levels.
Müller T; Erdmann C; Muhlack S; Bremen D; Przuntek H; Woitalla D
Mov Disord; 2006 Mar; 21(3):332-6. PubMed ID: 16211593
[TBL] [Abstract][Full Text] [Related]
26. Maximizing the benefit:risk ratio of levodopa therapy in Parkinson's disease.
Gottwald MD
Pharmacotherapy; 1999 Nov; 19(11 Pt 2):162S-8S. PubMed ID: 10555944
[TBL] [Abstract][Full Text] [Related]
27. Role of COMT inhibitors and dopamine agonists in the treatment of motor fluctuations.
Widnell KL; Comella C
Mov Disord; 2005; 20 Suppl 11():S30-7. PubMed ID: 15822107
[TBL] [Abstract][Full Text] [Related]
28. Issues important for rational COMT inhibition.
Dingemanse J
Neurology; 2000; 55(11 Suppl 4):S24-7; discussion S28-32. PubMed ID: 11147507
[TBL] [Abstract][Full Text] [Related]
29. [COMT inhibition with tolcapone].
Nervenarzt; 1996 Jul; 67(7 Suppl Comt-hemmu):1-8. PubMed ID: 9404535
[No Abstract] [Full Text] [Related]
30. Current treatment and future prospects of dopa-induced dyskinesias.
Mazzucchi S; Frosini D; Bonuccelli U; Ceravolo R
Drugs Today (Barc); 2015 May; 51(5):315-29. PubMed ID: 26097904
[TBL] [Abstract][Full Text] [Related]
31. Treatment options for early Parkinson's disease.
Stacy M; Brownlee HJ
Am Fam Physician; 1996 Mar; 53(4):1281-7. PubMed ID: 8629572
[TBL] [Abstract][Full Text] [Related]
32. Interventions to achieve tonic exposure to levodopa: delaying or preventing the onset of motor complications.
Luer MS
Pharmacotherapy; 1999 Nov; 19(11 Pt 2):169S-79S. PubMed ID: 10555945
[TBL] [Abstract][Full Text] [Related]
33. Treatment of levodopa-induced motor complications.
Stocchi F; Tagliati M; Olanow CW
Mov Disord; 2008; 23 Suppl 3():S599-612. PubMed ID: 18781681
[TBL] [Abstract][Full Text] [Related]
34. Factors associated with motor fluctuations and dyskinesia in Parkinson Disease: potential role of a new melevodopa plus carbidopa formulation (Sirio).
Stocchi F; Marconi S
Clin Neuropharmacol; 2010 Jul; 33(4):198-203. PubMed ID: 20414107
[TBL] [Abstract][Full Text] [Related]
35. Entacapone, a catechol-O-methyltransferase inhibitor, improves the motor activity and dopamine content of basal ganglia in a rat model of Parkinson's disease induced by Japanese encephalitis virus.
Hamaue N; Ogata A; Terado M; Tsuchida S; Yabe I; Sasaki H; Hirafuji M; Togashi H; Aoki T
Brain Res; 2010 Jan; 1309():110-5. PubMed ID: 19879254
[TBL] [Abstract][Full Text] [Related]
36. Avoidance of dyskinesia: preclinical evidence for continuous dopaminergic stimulation.
Jenner P
Neurology; 2004 Jan; 62(1 Suppl 1):S47-55. PubMed ID: 14718680
[TBL] [Abstract][Full Text] [Related]
37. Continuous dopaminergic therapy in Parkinson disease: time to stride back?
Stoessl AJ
Ann Neurol; 2010 Jul; 68(1):3-5. PubMed ID: 20583222
[No Abstract] [Full Text] [Related]
38. Tolcapone for Parkinson's disease.
Med Lett Drugs Ther; 1998 Jun; 40(1028):60-1. PubMed ID: 9629124
[No Abstract] [Full Text] [Related]
39. Catechol-O-methyltransferase inhibition improves levodopa-associated strength increase in patients with Parkinson disease.
Müller T; Kolf K; Ander L; Woitalla D; Muhlack S
Clin Neuropharmacol; 2008; 31(3):134-40. PubMed ID: 18520980
[TBL] [Abstract][Full Text] [Related]
40. Several classes of new drugs emerging for Parkinson disease.
Phillips P
JAMA; 1999 Sep; 282(10):929-31. PubMed ID: 10485664
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
